W M Clark

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators
    W M Clark
    Oregon Stroke Center, Portland, OR 97201, USA
    Stroke 31:811-6. 2000
  2. ncbi request reprint Potential of anticytokine therapies in central nervous system ischaemia
    W M Clark
    Oregon Stroke Center, Dept of Neurology UHS44, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201, USA
    Expert Opin Biol Ther 1:227-37. 2001
  3. ncbi request reprint A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients
    W M Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland, OR 97201, USA
    Neurology 57:1595-602. 2001
  4. ncbi request reprint Efficacy of antioxidant therapies in transient focal ischemia in mice
    W M Clark
    Oregon Stroke Center, Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
    Stroke 32:1000-4. 2001
  5. ncbi request reprint Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators
    W M Clark
    Oregon Stroke Center, Portland, OR 97201, USA
    Stroke 31:1234-9. 2000
  6. ncbi request reprint Efficacy of citicoline as an acute stroke treatment
    Wayne M Clark
    Department of Neurology CR131, Oregon Health Sciences University, Oregon Stroke Center, Portland, OR97201, USA
    Expert Opin Pharmacother 10:839-46. 2009
  7. ncbi request reprint Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
  8. ncbi request reprint A randomized efficacy trial of citicoline in patients with acute ischemic stroke
    W M Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA
    Stroke 30:2592-7. 1999
  9. ncbi request reprint Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents
    W M Clark
    Department of Neurology, Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Neuroimaging Clin N Am 9:465-73. 1999
  10. ncbi request reprint Citicoline treatment for experimental intracerebral hemorrhage in mice
    W Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201
    Stroke 29:2136-40. 1998

Research Grants

Collaborators

Detail Information

Publications18

  1. ncbi request reprint The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators
    W M Clark
    Oregon Stroke Center, Portland, OR 97201, USA
    Stroke 31:811-6. 2000
    ..We report here the results of the original study (part A), focusing on evaluating the safety and efficacy of rtPA given between 0 and 6 hours after stroke onset...
  2. ncbi request reprint Potential of anticytokine therapies in central nervous system ischaemia
    W M Clark
    Oregon Stroke Center, Dept of Neurology UHS44, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201, USA
    Expert Opin Biol Ther 1:227-37. 2001
    ..Although there are no current clinical 'anti-cytokine' treatment studies for stroke, experimental studies modulating IL-1 and TNF-alpha have shown neuroprotection...
  3. ncbi request reprint A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients
    W M Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland, OR 97201, USA
    Neurology 57:1595-602. 2001
    ..Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects...
  4. ncbi request reprint Efficacy of antioxidant therapies in transient focal ischemia in mice
    W M Clark
    Oregon Stroke Center, Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
    Stroke 32:1000-4. 2001
    ..In this study we investigated the neuroprotective efficacy of EGb and LA in a clinically relevant, transient focal central nervous system ischemic model...
  5. ncbi request reprint Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators
    W M Clark
    Oregon Stroke Center, Portland, OR 97201, USA
    Stroke 31:1234-9. 2000
    ..Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients <70 years old...
  6. ncbi request reprint Efficacy of citicoline as an acute stroke treatment
    Wayne M Clark
    Department of Neurology CR131, Oregon Health Sciences University, Oregon Stroke Center, Portland, OR97201, USA
    Expert Opin Pharmacother 10:839-46. 2009
    ..Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet...
  7. ncbi request reprint Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
    ..This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset...
  8. ncbi request reprint A randomized efficacy trial of citicoline in patients with acute ischemic stroke
    W M Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA
    Stroke 30:2592-7. 1999
    ..A previous dose-comparison trial in patients with acute stroke found that 500 mg of citicoline appeared to improve neurological outcome with minimal side effects...
  9. ncbi request reprint Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents
    W M Clark
    Department of Neurology, Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Neuroimaging Clin N Am 9:465-73. 1999
    ..The current status of other potential stroke therapies are also reviewed, including neuroprotective trials and agents designed to limit reperfusion injury...
  10. ncbi request reprint Citicoline treatment for experimental intracerebral hemorrhage in mice
    W Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201
    Stroke 29:2136-40. 1998
    ..The present study was designed to test whether treatment with citicoline reduces ischemic injury and improves functional neurological outcome in an experimental model of ICH...
  11. ncbi request reprint Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
    A Furlan
    Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 282:2003-11. 1999
    ..Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed...
  12. ncbi request reprint Temporal modulation of cytokine expression following focal cerebral ischemia in mice
    J K Hill
    Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Mail Code L220, 3181 Sam Jackson Park Road, Portland, OR 97201, USA
    Brain Res 820:45-54. 1999
    ....
  13. ncbi request reprint Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat
    W M Clark
    Department of Neurology, Oregon Health Sciences University, Portland, USA
    J Mol Neurosci 9:103-8. 1997
    ..5 +/- 0.2 (mean +/- SE) vs control 1.3 +/- 0.3 (p = 0.03). Infarct volume: doxycycline 56 +/- 18 mm3 vs control 158 +/- 44 mm3 (p = 0.03); This protective effect supports the role of doxycycline in reducing CNS reperfusion injury...
  14. ncbi request reprint Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia
    W M Clark
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Mol Chem Neuropathol 26:213-30. 1995
    ..At 4 and 7 d: only M phi accumulation, cellular morphology now similar to microglia. The results of this study indicate that early and persistent ICAM-1 expression occurs following CNS ischemia with associated leukocyte infiltration...
  15. ncbi request reprint Current status of neuroprotective agents in the treatment of acute ischemic stroke
    H L Lutsep
    Oregon Stroke Center, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, CR 131, Portland, OR 97201, USA
    Curr Neurol Neurosci Rep 1:13-8. 2001
    ..Ongoing clinical trials with novel agents are trying to enroll a more homogeneous population of stroke patients in an effort to demonstrate treatment benefit...
  16. ncbi request reprint Association of intracranial stenosis with cortical symptoms or signs
    H L Lutsep
    Oregon Stroke Center, Oregon Health Sciences University, Portland 97201, USA
    Neurology 55:716-8. 2000
    ..Fifteen percent (5/33) of patients with cortical symptoms or signs had symptomatic intracranial stenosis of 50% or more by MR angiography or angiography, compared with 0% (0/15) of those without such findings (p < 0.005)...
  17. ncbi request reprint Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment
    W M Clark
    Department of Neurology, Oregon Health Sciences University, Portland 97201
    Stroke 22:877-83. 1991
    ..This protective effect supports the active role of leukocytes in central nervous system reperfusion ischemic injury and offers potential for future therapy...
  18. pmc Drug eluting stents for symptomatic intracranial and vertebral artery stenosis
    J D Fields
    Interventional Neuroradiology, Department of Neurology Oregon Health and Science University, Portland, USA
    Interv Neuroradiol 17:241-7. 2011
    ....

Research Grants1

  1. Evaluation of Antioxidant Suppl in Focal CNS Ischemia
    Wayne Clark; Fiscal Year: 2003
    ..The information obtained from this project will be critical in planning future clinical stroke trials involving these agents. ..